Targeted quantitative analysis of superoxide dismutase 1 in cisplatin-sensitive and cisplatin-resistant human ovarian cancer cells

Jong Won Kim, Bei Nie, Heather Sahm, Dawn P G Brown, Tony Tegeler, Jin Sam You, Mu Wang

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Protein quantification in a complex protein mixture presents a daunting task in biochemical analysis. Antibody-based immunoassays are traditional methods for protein quantification. However, there are issues associated with accuracy and specificity in these assays, especially when the changes are small (e.g., <2-fold). With recent developments in mass spectrometry, monitoring a selected peptide, thus protein, in a complex biological sample has become possible. In this study, we demonstrate a simple mass spectrometry-based method for selective measurement of a moderately low abundant protein, superoxide dismutase 1 (SOD1), in cisplatin-sensitive and cisplatin-resistant human ovarian cancer cells. Selected-reaction-monitoring (SRM) technology was employed to specifically analyze the target peptides in a pair of human ovarian cancer cell lines: 2008/2008-C13*5.25 (cisplatin-sensitive/cisplatin-resistant, respectively). The observed 1.47-fold higher expression in the resistant cell line is consistent with findings by other approaches. This robust liquid chromatography/mass spectrometry (LC/MS) method provides a powerful tool for targeted proteomic verification and/or validation studies.

Original languageEnglish
Pages (from-to)700-704
Number of pages5
JournalJournal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
Volume878
Issue number7-8
DOIs
StatePublished - Mar 1 2010

Fingerprint

Ovarian Neoplasms
Cisplatin
Superoxide Dismutase
Cells
Mass spectrometry
Mass Spectrometry
Chemical analysis
Proteins
Cell Line
Peptides
Monitoring
Validation Studies
Liquid chromatography
Complex Mixtures
Immunoassay
Liquid Chromatography
Proteomics
Assays
Superoxide Dismutase-1
Technology

Keywords

  • Cisplatin drug resistance
  • Mass spectrometry
  • Ovarian cancer
  • Selected-reaction-monitoring
  • Superoxide dismutase 1

ASJC Scopus subject areas

  • Biochemistry
  • Analytical Chemistry
  • Cell Biology
  • Clinical Biochemistry

Cite this

Targeted quantitative analysis of superoxide dismutase 1 in cisplatin-sensitive and cisplatin-resistant human ovarian cancer cells. / Kim, Jong Won; Nie, Bei; Sahm, Heather; Brown, Dawn P G; Tegeler, Tony; You, Jin Sam; Wang, Mu.

In: Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Vol. 878, No. 7-8, 01.03.2010, p. 700-704.

Research output: Contribution to journalArticle

@article{16628ae075784536ba5ad936cf7af824,
title = "Targeted quantitative analysis of superoxide dismutase 1 in cisplatin-sensitive and cisplatin-resistant human ovarian cancer cells",
abstract = "Protein quantification in a complex protein mixture presents a daunting task in biochemical analysis. Antibody-based immunoassays are traditional methods for protein quantification. However, there are issues associated with accuracy and specificity in these assays, especially when the changes are small (e.g., <2-fold). With recent developments in mass spectrometry, monitoring a selected peptide, thus protein, in a complex biological sample has become possible. In this study, we demonstrate a simple mass spectrometry-based method for selective measurement of a moderately low abundant protein, superoxide dismutase 1 (SOD1), in cisplatin-sensitive and cisplatin-resistant human ovarian cancer cells. Selected-reaction-monitoring (SRM) technology was employed to specifically analyze the target peptides in a pair of human ovarian cancer cell lines: 2008/2008-C13*5.25 (cisplatin-sensitive/cisplatin-resistant, respectively). The observed 1.47-fold higher expression in the resistant cell line is consistent with findings by other approaches. This robust liquid chromatography/mass spectrometry (LC/MS) method provides a powerful tool for targeted proteomic verification and/or validation studies.",
keywords = "Cisplatin drug resistance, Mass spectrometry, Ovarian cancer, Selected-reaction-monitoring, Superoxide dismutase 1",
author = "Kim, {Jong Won} and Bei Nie and Heather Sahm and Brown, {Dawn P G} and Tony Tegeler and You, {Jin Sam} and Mu Wang",
year = "2010",
month = "3",
day = "1",
doi = "10.1016/j.jchromb.2010.01.013",
language = "English",
volume = "878",
pages = "700--704",
journal = "Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences",
issn = "1570-0232",
publisher = "Elsevier",
number = "7-8",

}

TY - JOUR

T1 - Targeted quantitative analysis of superoxide dismutase 1 in cisplatin-sensitive and cisplatin-resistant human ovarian cancer cells

AU - Kim, Jong Won

AU - Nie, Bei

AU - Sahm, Heather

AU - Brown, Dawn P G

AU - Tegeler, Tony

AU - You, Jin Sam

AU - Wang, Mu

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Protein quantification in a complex protein mixture presents a daunting task in biochemical analysis. Antibody-based immunoassays are traditional methods for protein quantification. However, there are issues associated with accuracy and specificity in these assays, especially when the changes are small (e.g., <2-fold). With recent developments in mass spectrometry, monitoring a selected peptide, thus protein, in a complex biological sample has become possible. In this study, we demonstrate a simple mass spectrometry-based method for selective measurement of a moderately low abundant protein, superoxide dismutase 1 (SOD1), in cisplatin-sensitive and cisplatin-resistant human ovarian cancer cells. Selected-reaction-monitoring (SRM) technology was employed to specifically analyze the target peptides in a pair of human ovarian cancer cell lines: 2008/2008-C13*5.25 (cisplatin-sensitive/cisplatin-resistant, respectively). The observed 1.47-fold higher expression in the resistant cell line is consistent with findings by other approaches. This robust liquid chromatography/mass spectrometry (LC/MS) method provides a powerful tool for targeted proteomic verification and/or validation studies.

AB - Protein quantification in a complex protein mixture presents a daunting task in biochemical analysis. Antibody-based immunoassays are traditional methods for protein quantification. However, there are issues associated with accuracy and specificity in these assays, especially when the changes are small (e.g., <2-fold). With recent developments in mass spectrometry, monitoring a selected peptide, thus protein, in a complex biological sample has become possible. In this study, we demonstrate a simple mass spectrometry-based method for selective measurement of a moderately low abundant protein, superoxide dismutase 1 (SOD1), in cisplatin-sensitive and cisplatin-resistant human ovarian cancer cells. Selected-reaction-monitoring (SRM) technology was employed to specifically analyze the target peptides in a pair of human ovarian cancer cell lines: 2008/2008-C13*5.25 (cisplatin-sensitive/cisplatin-resistant, respectively). The observed 1.47-fold higher expression in the resistant cell line is consistent with findings by other approaches. This robust liquid chromatography/mass spectrometry (LC/MS) method provides a powerful tool for targeted proteomic verification and/or validation studies.

KW - Cisplatin drug resistance

KW - Mass spectrometry

KW - Ovarian cancer

KW - Selected-reaction-monitoring

KW - Superoxide dismutase 1

UR - http://www.scopus.com/inward/record.url?scp=76549089792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76549089792&partnerID=8YFLogxK

U2 - 10.1016/j.jchromb.2010.01.013

DO - 10.1016/j.jchromb.2010.01.013

M3 - Article

C2 - 20117967

AN - SCOPUS:76549089792

VL - 878

SP - 700

EP - 704

JO - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

JF - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

SN - 1570-0232

IS - 7-8

ER -